Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Biomedicines|February 25, 2022
A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational EvidencesAlessandro De Vita, Silvia Vanni, Giacomo Miserocchi, et al.
Scientific Reports|March 4, 2021
Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancerAlessandro De Vita, Chiara Liverani, Roberto Molinaro, et al.
Future Oncology (London, England)|December 20, 2014
Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case reportAlberto Bongiovanni, Marianna Ricci, Nada Riva, et al.
Therapeutic Advances in Medical Oncology|July 5, 2022
Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectivesSilvia Vanni, Alessandro De Vita, Lorena Gurrieri, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumorsSilvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.
Heliyon|December 17, 2024
Exploring nanotechnology solutions for improved outcomes in gastrointestinal stromal tumorsSofia Gabellone, Silvia Vanni, Valentina Fausti, et al.
International Journal of Molecular Sciences|April 28, 2023
Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical NeedSilvia Vanni, Valentina Fausti, Eugenio Fonzi, et al.
International Journal of Molecular Sciences|August 25, 2016
Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish ModelLaura Mercatali, Federico La Manna, Arwin Groenewoud, et al.
Biology Open|November 30, 2016
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish modelChiara Liverani, Federico La Manna, Arwin Groenewoud, et al.
Frontiers in Endocrinology|February 6, 2023
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumorsChiara Liverani, Chiara Spadazzi, Toni Ibrahim, et al.
Pageof 4